Streetbeat News

Revenues

LRHC

La Rosa Holdings Corp. (LRHC) has acquired its seventh real estate brokerage franchisee, La Rosa Realty Winter Garden LLC, with a revenue of $1.4M and positive cash flow in 2023. The acquisition is part of La Rosa's de-franchising strategy aimed at achieving an annual revenue run rate of $100 million by the end of 2024 and becoming profitable by early 2025. The company's unique business model offers real estate agents a revenue share or an annual fee-based model with 100% commissions, contributing to its growth in agent count.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:16 pm

EIC

Eagle Point Income (EIC) reported a Q4 EPS of $0.54, up 10.2% from $0.49 YoY, with sales increasing 54.53% to $8.52M from $5.51M YoY.

Portfolio Pulse from saritha@benzinga.com

February 22, 2024 | 1:14 pm

PXD

Pioneer Natural Resources (PXD) reported Q4 2023 earnings of $5.26 per share, missing the $5.48 estimate. However, their sales of $5.22B exceeded the $4.04B estimate, marking a 48.38% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:11 pm

AMIX

Autonomix Medical has secured principal investigators and completed clinical training for its first human study, a proof-of-concept clinical trial targeting the pancreatic cancer market through transvascular RF ablation. The company expects to commence patient enrollment imminently, aiming at the multi-billion-dollar pancreatic cancer market.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:08 pm

MYNZ

Mainz Biomed has announced a distribution partnership with Praxisdienst for its ColoAlert product, a diagnostic tool for early detection of colorectal cancer. This partnership aims to enhance the availability and accessibility of ColoAlert, potentially increasing Mainz Biomed's market presence and revenue from this product.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:05 pm

XPEL

XPEL, a leading provider of protective films and coatings, has announced its target for revenue growth in 2024, aiming for an approximate increase of 15%. This ambitious goal reflects the company's confidence in its business strategy and market demand for its products.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:04 pm

MDAI

Spectral AI, Inc. (NASDAQ:MDAI) has received UKCA authorization for its DeepView AI-Burn software, enabling the sale of its DeepView System in the UK for burn wound diagnosis. The company plans to deploy six devices in the UK for customer evaluation and expects to generate revenue in H2 2024. This authorization also facilitates expansion into the Middle East. The DeepView System, with a 92% accuracy rate, significantly improves upon the current standard of care for assessing burn wounds, which has a 50% to 75% accuracy rate.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:03 pm

XPEL

XPEL reported Q4 earnings of $0.43 per share, missing the consensus estimate of $0.48, but saw a 43.33% increase over the previous year. Sales reached $105.54M, exceeding estimates of $96.63M and marking a 34.48% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:03 pm

CPT

Camden Prop Trust (NYSE:CPT) has been evaluated by 9 analysts over the last three months, showing a mix of bullish to bearish sentiments. The average 12-month price target is $105.67, down 10.14% from the previous $117.60. Recent analyst actions include ratings and price target adjustments by firms like Goldman Sachs, Barclays, and Morgan Stanley, reflecting changes in market conditions and company performance. Camden's financial health is strong, with a market capitalization above industry averages, a revenue growth rate of 4.55%, and impressive net margin and ROE figures.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 1:00 pm

RITM

Analyst ratings for Rithm Capital (NYSE:RITM) show a mix of bullish sentiments with recent upgrades in price targets, reflecting positive expectations. The average 12-month price target is now $12.12, up 8.5% from the previous $11.17. Despite the optimistic analyst outlook, Rithm Capital's financials reveal challenges, including a -21.17% revenue decline, below-industry-standard net margin, ROE, and ROA, and a high debt-to-equity ratio of 4.19.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 1:00 pm